Restrictive eating disorders A joint advisory from obesity and nutrition societies notes that restrictive eating disorders are a general contraindication to GLP-1 use
Qualifications GLP-1 cases often involve regulatory history, FDA warnings, and evolving medical research
Research shows that these medications can lower the risk of major cardiac-related events, including heart attack and stroke, especially in those with type 2 diabetes or existing heart disease, says Brynna Connor, MD, ABFM, a diplomate of the American Academy of Anti-Aging/Regenerative Medicine
GLP-1 receptor agonists affect more than glucose metabolismthey activate receptors throughout the brain involved in mood regulation and attention pathways
New online matching services, such as Berry Street and Fay, are betting big on recruiting crops of specialized GLP-1 nutritional counselors
Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society, Obesity Pillars
